Found: 12
Select item for more details and to access through your institution.
Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S171, doi. 10.1016/S2152-2650(21)02367-3
- By:
- Publication type:
- Article
P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S88, doi. 10.1016/S2152-2650(21)02224-2
- By:
- Publication type:
- Article
OAB-053: Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S38, doi. 10.1016/S2152-2650(21)02133-9
- By:
- Publication type:
- Article
OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02122-4
- By:
- Publication type:
- Article
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 820, doi. 10.1634/theoncologist.2018-0433
- By:
- Publication type:
- Article
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-39594-4
- By:
- Publication type:
- Article
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01330-3
- By:
- Publication type:
- Article
Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.
- Published in:
- Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-04270-3
- By:
- Publication type:
- Article